- Research article
- Open Access
Investigation on in vitro dissolution rate enhancement of indomethacin by using a novel carrier sucrose fatty acid ester
© Sunil et al.; licensee BioMed Central Ltd. 2012
Received: 22 May 2012
Accepted: 19 July 2012
Published: 19 July 2012
Background and the purpose of the study
The purpose of the present investigation was to characterize and evaluate solid dispersions (SD) of indomethacin by using a novel carrier sucrose fatty acid ester (SFE 1815) to increase its in vitro drug release and further formulating as a tablet.
Indomethacin loaded SD were prepared by solvent evaporation and melt granulation technique using SFE 1815 as carrier in 1:0.25, 1:0.5 1:0.75 and 1:1 ratios of drug and carrier. Prepared SD and tablets were subjected to in vitro dissolution studies in 900 mL of pH 7.2 phosphate buffer using apparatus I at 100 rpm. The promising SD were further formulated as tablets using suitable diluent (DCL 21, Avicel PH 102 and pregelatinised starch) to attain the drug release similar to that of SD.. The obtained dissolution data was subjected to kinetic study by fitting the data into various model independent models like zero order, first order, Higuchi, Hixon-Crowell and Peppas equations. Drug and excipient compatibility studies were confirmed by fourier transform infrared spectroscopy, X-ray diffraction, differential scanning calorimetry and scanning electron microscopy.
The in vitro dissolution data exhibited superior release from formulation S6 with 1:0.5 drug and carrier ratio using solvent evaporation technique than other SDs prepared at different ratio using solvent evaporation and melt granulation technique. The in vitro drug release was also superior to that of the physical mixtures prepared at same ratio and also superior to SD prepared using common carriers like polyvinyl pyrollidone and PEG 4000 by solvent evaporation technique. Tablets (T8) prepared with DCL21 as diluent exhibited superior release than the other tablets. The tablet formulation (T8) followed first order release with Non-Fickian release.
SFE 1815 a novel third generation carrier can be used for the preparation of SD for the enhancement of in vitro drug release of indomethacin an insoluble drug belonging to BCS class II.
The therapeutic efficacy of a drug product intended to be administered by the oral route depends upon its absorption in the gastro-intestinal tract to end with bioavailability. It is well established that dissolution is recurrently the rate-limiting step in the gastrointestinal absorption of a drug from a solid dosage form which belongs to BCS class II (low soluble and high permeable). The drug release from poorly soluble drugs has been shown to be unpredictable and still remains a problem to the pharmaceutical industry . Several methods that have been employed to improve the solubility of poorly water soluble drugs include increasing the particle surface area available for dissolution by milling , improving the wettability with surfactants or doped crystals , decreasing crystallinity by preparing a solid dispersion , use of inclusion compounds such as cyclodextrin derivatives , use of polymorphic forms or solvated compounds  and use of salt forms. There are several advantages and disadvantages for the above given methods. Solid dispersions (SD) represent an ideal pharmaceutical technique for increasing the dissolution, absorption and therapeutic efficacy of drugs with poor aqueous solubility. The term “solid dispersion” refers to the dispersion of one or more active ingredients in an inert carrier or matrix in the solid state prepared by melting, solvent, or melting solvent methods  which has been used by various researchers who have reported encouraging results with different drugs . The method of preparation and the type of the carrier used are important in influencing the properties of such solid dispersions . Among the carriers used in the formation of solid dispersions, polyethylene glycol and polyvinyl pyrrolidone are the most commonly used. The first generation (urea) and second generation (PEG, polyvinyl pyrrolidone, HPMC, hydroxylpropyl cellulose, starch derivatives, cyclodextrins) of carriers have many disadvantages when compared to the use of third generation carriers (poloxamer, gelucire, sucrose fatty acid esters) which are non-ionic and led to development of superior solid dispersions.
Sucrose fatty acid esters (SFE) are nonionic surface active agents which are mono-, di-, and tri-esters of sucrose with fatty acids, manufactured from purified sugar or hydrogenated edible tallow or edible vegetable oils. These consist of sucrose residues as the hydrophilic group or polar head and fatty acid residues as the lipophilic group or non-polar head with a unique emulsification property that tolerates any temperature variation [10, 11]. SFE are currently regulated by the U.S. Food and Drug Administration (FDA) as food additives under chapter 21, section 172.859 of the Federal Code of Regulations (CFR). However, studies of SFE in the area of commonly used tablet formulations are limited and emphasize using specific types of SFE for particular approaches. These are non-toxic and biodegradable, as they can be enzymatically hydrolyzed to sucrose and fatty acids prior to intestinal absorption or excreted in faeces, depending on the degree of esterfication with a wide range of HLB values 1 – 16 [12, 13].
The present investigation was focused on exploring sucrose fatty acid ester as a drug carrier to increase the drug solubility and the dissolution rate of indomethacin by formation of solid dispersions using various methods. The dissolution characteristics and physicochemical modification of the indomethacin-SFE solid dispersions were investigated by in vitro dissolution test, FTIR, XRD, SEM and thermal analysis (DSC). These solid dispersions were formulated into tablets after optimizing with suitable diluent used in the study and were evaluated for physicochemical characterization.
Indomethacin was a gift sample from Macleods pharmaceuticals Ltd. India. Sucrose fatty acid ester 1815 was obtained from Mitsubishi-Kagaku Foods Corporation, Japan. Avicel PH 102 was obtained from FMC Biopolymer. DCL 21 was purchased from Zeel Pharmaceuticals, India. All other chemicals were of reagent grade and used as received.
Composition of solid dispersions
Composition of different SD using SFE 1815
Ratio (Drug: polymer)
Preparation of solid dispersions
Melt granulation method
Accurately weighed amounts of carrier were placed in an aluminum pan on a hot plate and melted, with constant stirring, at a temperature of about 50 °C. An accurately weighed amount of indomethacin was incorporated into the melted carrier with stirring to ensure homogeneity. The mixture was heated until a clear homogeneous melt was obtained. The pan was then removed from the hot plate and allowed to cool at room temperature and the obtained damp mass is passed through sieve no #40. The granules obtained were transferred to a polybag and stored in desiccator for further studies.
Solvent evaporation method
Accurately weighed amounts of indomethacin and carrier (SFE 1815) were dissolved in minimum quantities of methanol in a china dish. The solution was stirred till slurry was formed. The solvent was evaporated under reduced pressure at 40 °C, and the resulting residue was dried under vacuum for 3 h, stored in a desiccator at least overnight, ground in a mortar, and passed through mesh no #40.
Physical mixtures were obtained by pulverizing accurately weighed amounts of drug and polymer in a glass mortar and carefully mixed until a homogeneous mixture was obtained. Drug and carrier ratio of 1:0.5 were prepared and subsequently stored at room temperature in desiccator.
Preparation of tablets
Formulae of tablets
Indo + SD
Avicel PH 102
PVP K 30
In vitro dissolution studies
Powder equivalent to indomethacin 25 mg for SD and tablets were introduced into dissolution medium. The dissolution medium is 900 mL of phosphate buffer pH 7.2, rotational speed of the basket was set at 100 rpm at 37 ± 0.5 °C. Aliquots (5 ml each) were withdrawn at predetermined time intervals by means of a syringe fitted with a 0.45 μm pre-filter and immediately replaced with 5 mL of fresh medium maintained at 37 ± 0.5 °C. The samples were analyzed for indomethacin using U.V. double beam Elico SL 210 model at 318 nm. For comparison, dissolution studies of pure indomethacin and INDOCAP marketed capsules along with PM and SD prepared with polyvinyl pyrollidone (PVP) and PEG 4000 at drug and polymer ratio of 1:0.5 employing solvent evaporation technique were also performed. All the dissolution experiments were carried out in triplicate. Comparison of dissolution profiles was done to quantify the difference in rate and extent of drug release as influenced by the formulation and process variables in order to find out the mode of drug release and their kinetics.
As a model-dependent approach, the dissolution data was fitted to five popular release models such as zero-order, first-order, Higuchi , Hixon-Crowel  and Korsmeyer -peppas equations. The order of drug release from matrix systems was described by using zero order kinetics or first orders kinetics. The mechanism of drug release from matrix systems was studied by using Higuchi and Hixon-Crowel equation. Model with the highest coefficient correlation (r) was judged to be a more appropriate model for the dissolution data.
Mathematical models for comparison of dissolution profiles
Fourier transform infrared spectroscopy
FTIR spectra can be used to detect drug excipient interactions by following the shift in vibrational or stretching bands of key functional groups. FTIR spectra were obtained by using Alpha FTIR spectrophotometer (Bruker Optik GmbH, Germany). All the spectra were analyzed using OPUS 6.5 software. Samples were prepared by KBr pellet method, which had been prepared by gently mixing 1 mg of the sample with 200 mg of KBr. The spectra were scanned over a wave number range of 4000 - 500 cm−1.
The physical state of indomethacin in different samples was evaluated with X-ray powder diffraction. XRD is a powerful tool in detecting crystallinity. The X-ray diffraction patterns were recorded on X-Ray diffractometer (PW 1729, Philips, Netherlands). XRD patterns were recorded using monochromatic Cu Kα radiation with Nitrogen filter at a voltage of 40 keV and a current of 40 mA. The sample was analyzed over 2θ range of 5-30° and the data was processed with Diffrac Plus V1.01 software.
Differential scanning calorimetry
DSC is a frequently used thermo analytical technique that generates data on melting endotherms and glass transitions. DSC was performed utilizing Mettler DSC 821 (Mettler-Toledo, Switzerland). Samples of 3-4 mg were encapsulated and hermetically sealed in flat bottomed aluminum pan with crimped on lid. Samples were allowed to equilibrate for 1 min and then heated in a nitrogen atmosphere over a temperature range from 25 °C to 240 °C with a heating rate of 5 °C/min. An empty aluminum pan is served as reference. Nitrogen was used as a purge gas, at the flow rate of 20 mL/min for all the studies. Reproducibility was checked by running the sample in triplicate. Thermograms were obtained by the STARe SW 9.10 software and reported.
Scanning electron microscopy
SEM has been employed to study the morphology of the samples. The samples were mounted on the SEM sample stab, using a double sided sticking tape and coated with gold (200 A°) under reduced pressure (0.001 torr) for 5 min using an ion sputtering device (Jeol JFC-1100 E, Japan). The gold coated samples were observed under the SEM (JEOL JSM-840A, Japan) and photomicrographs of suitable magnifications were obtained with the aid of a software system (LINKISIS, Oxford, UK).
Results and discussion
In vitro dissolution studies
It is well known from the literature and practical knowledge that the SD are unstable as such, but stable when formulated as a tablet dosage form. The best SD (S6) prepared by solvent evaporation technique in 1:0.5 of drug: SFE1815 ratio was selected for the development of tablets, which gave a superior and enhanced release profile than SD prepared by melt granulation using same carrier, SD prepared by common carriers by solvent evaporation technique and PM.
Even though pregelatinised starch is more soluble than Avicel PH102 the percent of drug released from the tablets was less when compared to Avicel PH102. The possible reason for that release could be the swelling nature of pregelatinsed starch . As the concentration of the pregelatinized starch was increased, the percent of drug release decreased, which is one of the reason for its use in the development of sustained release tablets . Tablets prepared with DCL 21 as diluent gave better release than those prepared with Avicel PH 102 due to the more hydrophilic nature and solubility of DCL 21.
The drug release of indomethacin from the formulations T2 and T3 followed zero order kinetics which was indicated by higher ‘r’ values of zero order release model. T1, T4, T5, T6, T7, T8, and T9 followed first order release model which was indicated by the higher ‘r’ value.
Kinetic models of core tablets
Fourier transform infrared spectroscopy
Pure indomethacin spectra showed characteristic peaks at 3020 cm–1 (aromatic C-H stretching), 2965 cm–1 (C-H stretching vibrations), 1761 cm–1 (C = O stretching vibrations), 1261 cm–1 (asymmetric aromatic O-C stretching), 1086 cm−1 (symmetric aromatic O-H stretching).
Differential scanning calorimetry
Scanning electron microscopy
This study clearly shows that SD of indomethacin with SFE 1815 employing solvent evaporation technique improves their dissolution rates. Solvent evaporation techniques used in the present study requires very few quantity of organic solvent and absence of specialized equipment. Mechanisms involved are solubilisation and improved wetting of the drug  in the SFE 1815 rich micro-environment formed at the surface of drug crystals after dissolution of the polymer . Solid dispersions formulated with SFE 1815 improved the dissolution rate compared with physical mixtures and SD formulated using PVP and PEG 4000 at the same concentrations. As SFE 1815 belongs to third generation by virtue of their efficiency to increase the surface area and wide range of HLB, these are more efficient than other commonly used carriers to increase the solubility and dissolution. There are no reports to date on the usage of SFE 1815 as carriers. The crystallinity of the drugs was reduced in all solid dispersions which were evident from the XRD graphs and decreased intensity of the peaks from DSC thermograms. The same enhanced release was observed from the SD formulated as tablet dosage form with DCL21 as diluent.
The author S. A. Sunil is thankful to UGC (University Grants Commission, India) for awarding senior research fellowship for carrying out this research. One of the authors S. A. Sunil is thankful to B. Janaki Ram, M. Chaithanya Krishna and G. Sirisha for providing valuable information to carry out this research work.
- Ghebremeskel AN, Vemavarapu C, Lodayam M: Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm. 2007, 328: 119-129. 10.1016/j.ijpharm.2006.08.010.View ArticlePubMedGoogle Scholar
- Habib FS, Attia MA: Effect of particle size on the dissolution rate of monophenylbutazone solid dispersion in presence of certain additives. Drug Dev Ind Pharm. 1985, 11: 2009-2019. 10.3109/03639048509087765.View ArticleGoogle Scholar
- Chow AHL, Hsia CK, Gordon JD, Young JWM, Vargha-Butler EI: Assessment of wettability and its relationship to the intrinsic dissolution rate of doped phenytoin crystals. Int J Pharm. 1995, 126: 21-28. 10.1016/0378-5173(95)04060-9.View ArticleGoogle Scholar
- Flego C, Lovrecich M, Rubessa F: Dissolution rate of griseofulvin from solid dispersion with poly(vinylmethylether: maleic anhydride). Drug Dev Ind Pharm. 1988, 14: 1185-1202. 10.3109/03639048809151928.View ArticleGoogle Scholar
- Pitha J: Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J Pharm Sci. 1985, 74: 987-990. 10.1002/jps.2600740916.View ArticlePubMedGoogle Scholar
- Sekiguchi K, Kanke M, Tsuda Y, Ishida K, Tsuda T: Dissolution behavior of solid drugs. III. Determination of the transition temperature between the hydrate and anhydrous forms of phenobarbital by measuring their dissolution rates. Chem Pharm Bull. 1973, 21: 1592-1600. 10.1248/cpb.21.1592.View ArticleGoogle Scholar
- Chiou WL, Riegelman S: Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971, 60: 1281-1302. 10.1002/jps.2600600902.View ArticlePubMedGoogle Scholar
- Sheu MT, Yeh CM, Sokoloski TD: Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm. 1994, 103: 137-146. 10.1016/0378-5173(94)90094-9.View ArticleGoogle Scholar
- Otsuka M, Onone M, Matsuda Y: Hygroscopic stability and dissolution properties of spray-dried solid dispersion of furosemide with Eudragit. J Pharm Sci. 1996, 82: 32-38.View ArticleGoogle Scholar
- Garti N, Clement V, Leser M, Aserin A, Fanun M: Sucrose ester microemulsions. J Mol Liq. 1999, 80: 253-96.View ArticleGoogle Scholar
- Muller AS, Gagnaire J, Queneau Y, Karaoglanian M, Maitre JP, Bouchu A: Winsor behaviour of sucrose fatty acid esters: choice of the cosurfactant and effect of the surfactant composition. Colloids Surf A: Physicochem Eng Aspects. 2002, 203: 55-66. 10.1016/S0927-7757(01)01067-6.View ArticleGoogle Scholar
- Shigeoka T, Izawa O, Kitazawa K, Yamauchi F: Studies on the metabolic fate of sucrose esters in rats. Food Chem Toxicol. 1984, 22: 409-14. 10.1016/0278-6915(84)90321-1.View ArticlePubMedGoogle Scholar
- Noker PE, Lin TH, Hill DL, Shigeoka T: Metabolism of 14C-labelled sucrose esters of stearic acid in rats. Food Chem Toxicol. 1997, 35: 589-95. 10.1016/S0278-6915(97)00012-4.View ArticlePubMedGoogle Scholar
- Higuchi T: Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963, 52: 1145-1149. 10.1002/jps.2600521210.View ArticlePubMedGoogle Scholar
- Hixson AW, Crowell JH: Dependence of reaction velocity upon surface and agitation. I. Theoretical considerations. Ind Eng Chem. 1931, 23: 923-931. 10.1021/ie50260a018.View ArticleGoogle Scholar
- Peppas NA: Analysis of fickian and non-fickian drug release from polymers. Pharm Acta Helv. 1985, 60: 110-111.PubMedGoogle Scholar
- Rakesh PP, Dhaval JP, Dipen BB, Jayvadan KP: Physicochemical characterization and dissolution study of solid dispersions of furosemide with polyethylene glycol 6000 and polyvinylpyrollidone K30. Dissolution technologies. 2008, 15: 17-25.View ArticleGoogle Scholar
- Mahmoud E, Gihan F, Mohamed F: Improvement of solubility and dissolution rate of indomethacin by solid dispersions n Gelucire 50/13 and PEG4000. Saudi Pharmaceutical Journal. 2009, 17: 217-225. 10.1016/j.jsps.2009.08.006.View ArticleGoogle Scholar
- Zelko R, Orban A, Suvegh K: Tracking of the physical ageing of amorphous pharmaceutical polymeric excipients by positron annihilation spectroscopy. J Pharm Biomed Anal. 2006, 40: 249-254. 10.1016/j.jpba.2005.07.014.View ArticlePubMedGoogle Scholar
- Husband FA, Samey DB, Barnard MJ, Wilde PJ: Comparison of foaming and interfacial properties of pure sucrose monolaurates, dilaurate and commercial preparations. Food Hydrocolloids. 1998, 12: 237-44. 10.1016/S0268-005X(98)00036-8.View ArticleGoogle Scholar
- Tual A, Bourles E, Barey P, Houdoux A, Desprairies M, Courthaudon JL: Effect of surfactant sucrose ester on physical properties of dairy whipped emulsions in relation to those of O/W interfacial layers. J Colloid Interf Sci. 2006, 295: 495-503. 10.1016/j.jcis.2005.09.010.View ArticleGoogle Scholar
- Levina M, Ali R, Rajabi S: The Influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci. 2004, 93: 2746-2754. 10.1002/jps.20181.View ArticlePubMedGoogle Scholar
- Suvakanta D, Murthy PN, Lilakanta N, Chowdhury P: Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica drug research. 2010, 67: 217-223.Google Scholar
- Ahuja N, Katare OP, Singh B: Studies on dissolution enhancement and mathematical modelling of drug release of a poorly water-soluble drug using water soluble carriers. Eur J Pharm Biopharm. 2007, 65: 26-38. 10.1016/j.ejpb.2006.07.007.View ArticlePubMedGoogle Scholar
- Craig DQM: The mechanism of drug release from solid dispersion in water-soluble polymers. Int J Pharm. 2002, 231: 131-144. 10.1016/S0378-5173(01)00891-2.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.